Assembly Biosciences Inc./$ASMB

1D1W1MYTD1Y5YMAX

About Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Ticker
$ASMB
Sector
Health
Primary listing
NASDAQ
Employees
73
Headquarters
South San Francisco, United States
Website
www.assemblybio.com

ASMB Metrics

BasicAdvanced
$481M
-
-$0.00
1.09
-

Bulls say / Bears say

Assembly exercised its option to share 40% of U.S. development costs and profits for the HSV helicase-primase inhibitor program, giving shareholders greater participation in potential commercial upside while GS-1179 is expected to enter Phase 2 by year-end 2026. (GlobeNewswire)
Liquidity is a major near-term strength: Assembly reported $320.4 million in cash, cash equivalents and marketable securities at June 30, 2026, and expects funding into 2029 when including Gilead’s scheduled $75 million extension payment. (SEC Form 10-Q)
ABI-6250 is advancing into multiple Phase 2 opportunities: chronic HDV is targeted for the fourth quarter of 2026 and cholestatic liver diseases such as PBC and PSC for the first quarter of 2027; Phase 1a data supported oral dosing, target engagement and continued development. (SEC Form 10-Q)
Assembly remains a clinical-stage biotech with no approved products, recurring operating losses, and no product-sales revenue; it may ultimately need additional financing despite its current runway. (SEC Form 10-Q)
The May 2026 financing raised $115 million gross, but the capital structure includes approximately 9.5 million outstanding warrants plus options and other equity awards, creating meaningful dilution overhang for common shareholders. (SEC Form 10-Q)
The HSV opportunity is heavily dependent on Gilead: Gilead controls further development and commercialization, selected GS-1179 for Phase 2 while not planning to advance ABI-5366 further at this time, and the program remains unapproved with efficacy and safety still unproven. (SEC Form 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.

Funds containing ASMB

AllEURGBP
Funds
Fund name
Fund size
$ASMB weighting
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.01%
SPDR Russell 2000 US Small Cap£R2SC
£4.1B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.